The popular weight loss drug Wegovy is now available to children as young as 12. Danish manufacturer Novo Nordisk announced that the Food and Drug Administration had extended the drug's approval to include children. It had previously received regulatory approval for use in adults last year. In clinical trials, teens aged 12 to 17 who took the weekly injection lost 14 percent of their body weight over 64 weeks. This nearly matches the trials for adults, where recipients lost 15 percent of their weight after 68 weeks. Wegovy, and its sister drug Ozempic, have rocketed to popularity in 2022 because...